» Articles » PMID: 11306508

Lysophosphatidic Acid Promotes Matrix Metalloproteinase (MMP) Activation and MMP-dependent Invasion in Ovarian Cancer Cells

Overview
Journal Cancer Res
Specialty Oncology
Date 2001 Apr 18
PMID 11306508
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer is an highly metastatic disease characterized by ascites formation and diffuse i.p. adhesion, invasion, and metastasis. Levels of lysophosphatidic acid (LPA) are elevated in the plasma of patients with ovarian carcinoma, including 90% of patients with stage I disease, suggesting that LPA may promote early events in ovarian carcinoma dissemination. Expression of matrix metalloproteinases (MMPs) is also up-regulated in ovarian cancer tissues and ascites, and numerous studies have provided evidence for a direct role of MMPs in i.p. invasion and metastasis. Using three-dimensional type I collagen cultures or immobilized beta1 integrin subunit-specific antibodies, we previously demonstrated that beta1 integrin clustering promotes activation of proMMP-2 and processing of membrane type 1 MMP in ovarian cancer cells (S. M. Ellerbroek et al., Cancer Res., 59: 1635-1641, 1999). In the current study, the effect of LPA on MMP expression and invasive activity was investigated. Treatment of ovarian cancer cells with pathophysiological levels of LPA increased cellular adhesion to type I collagen and beta1 integrin expression. A significant up-regulation of MMP-dependent proMMP-2 activation was observed in LPA-treated cells, leading to enhanced pericellular MMP activity. As a result of increased MMP activity, haptotactic and chemotactic motility, in vitro wound closure, and invasion of a synthetic basement membrane were enhanced. These data indicate that LPA contributes to metastatic dissemination of ovarian cancer cells via up-regulation of MMP activity and subsequent downstream changes in MMP-dependent migratory and invasive behavior.

Citing Articles

The Role of EMT-Related lncRNAs in Ovarian Cancer.

Lampropoulou D, Papadimitriou M, Papadimitriou C, Filippou D, Kourlaba G, Aravantinos G Int J Mol Sci. 2023; 24(12).

PMID: 37373222 PMC: 10298523. DOI: 10.3390/ijms241210079.


Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics.

Chen M, Lei N, Tian W, Li Y, Chang L Ther Adv Med Oncol. 2022; 14:17588359221118010.

PMID: 35983027 PMC: 9379276. DOI: 10.1177/17588359221118010.


The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer.

Cunningham R, Hansen C Clin Sci (Lond). 2022; 136(3):197-222.

PMID: 35119068 PMC: 8819670. DOI: 10.1042/CS20201474.


The role of MMP-14 in ovarian cancer: a systematic review.

Caroline Vos M, van der Wurff A, van Kuppevelt T, Massuger L J Ovarian Res. 2021; 14(1):101.

PMID: 34344453 PMC: 8336022. DOI: 10.1186/s13048-021-00852-7.


The Role of Platelet Cell Surface P-Selectin for the Direct Platelet-Tumor Cell Contact During Metastasis Formation in Human Tumors.

Fabricius H, Starzonek S, Lange T Front Oncol. 2021; 11:642761.

PMID: 33791226 PMC: 8006306. DOI: 10.3389/fonc.2021.642761.